NovaTears, the first and only water-free topical eye drop treatment developed to treat patients with DED, is now distributed in New Zealand and has received registrational approval for distribution in Australia. It is being distributed by AFT Pharmaceuticals.
Professor Christian Roesky, managing director and CEO, of Novaliq said, “NovaTears is a first-in-class treatment for this common and highly underserved ophthalmic disease. (It) is a clinically validated treatment that significantly improves signs and symptoms of patients suffering from dry eye disease. We know from our clinical studies that NovaTears immediately stabilises the lipid layer and restores the natural tear film of the eye over time. I am confident that dry eye patients in Australasia will greatly benefit from this breakthrough innovation.”
According to Novaliq, NovaTears eye drops combine high efficacy with great comfort. Signs and subjective symptoms of DED are significantly reduced without causing blurry vision after application. NovaTears is pure, and therefore has no side effects related to preservatives or other additives.
“We are thrilled to be able to offer patients a novel ophthalmic treatment that addresses signs and symptoms of evaporative DED and MGD,” said Dr. Hartley Atkinson, CEO of AFT. “NovaTears is a first-in-class, water-free and preservative-free treatment that strengthens the lipid layer of the tear film thereby preventing evaporation. It is a welcome addition to our eye care line, one that will provide superior benefits to patients.”
